IFNA1 and Cirrhosis: evaluated 114 patients from various German centers receiving a 2mg/day BLV therapy were followed-up for 38 ± 17.6 weeks: 59 patients had cirrhosis, of which 4 were Child-Pugh B and 1 was Child-Pugh C; 55 patients had previously received Peg-IFNα therapy.